# US 2010/0168146 A1 · Composition Comprising (R)-Spiro[L-Azabicyclo[2.2.2]Octane-3,2'(3'H)-Furo[2,3-B]Pyridine (AZD0328) and its Use in the Treatment of Alzheimer's Disease, ADHD or Cognitive Dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168146 A1
- Document ID: US20100168146A1
- Status: Published application
- Kind: A1
- Application number: 12/531,802
- Filed: 2008-03-18
- Published: 2010-07-01
- Earliest claimed: 2008-03-18
- Inventors: Stacy A. Castner; Thomas Hudzik; Donna L. Maier; Ladislav Mrzljak; Timothy Piser; Jeff S. Smith; Dan Widzowski; Graham Williams
- Web page: https://patentgrep.com/patent/US20100168146A1

## CPC

- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprising (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine (AZD0328) and its use in the treatment of subjects suffering from schizophrenia, Alzheimer's disease or other conditions with impaired cognitive function.

## Claims

### Claim 1

A method of treating a subject suffering from a neurological or psychiatric condition comprising:
administering to a subject in need thereof, at least one therapeutically effective dose in the range of about 0.0005 milligram to about 2.0 milligram of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo [2,3-b]pyridine].

### Claim 2 (depends on 1)

A method according to claim 1, wherein said neurological or psychiatric condition is selected from Alzheimer's Disease, Attention-Deficit/Hyperactivity Disorder (ADHD), Cognitive dysfunction in association with Schizophrenia or Cognitive dysfunction.

### Claim 3 (depends on 2)

A method according to claim 2 providing relief of memory loss or cognitive deficiency in said subject.

### Claim 4

A method of providing relief of memory loss or cognitive deficiency in a subject with Alzheimer's Disease, Attention-Deficit/Hyperactivity Disorder (ADHD), Cognitive dysfunction in association with Schizophrenia or Cognitive dysfunction, comprising:
administering to a patient in need thereof, at least one therapeutically effective dose in the range of about 0.0005 milligram to about 2.0 milligram of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine].

### Claim 5

A method to ameliorate cognitive deficits in patients with schizophrenia comprising:
administering to a patient in need thereof, at least one therapeutically effective dose in the range of about 0.0005 milligram to about 2.0 milligram of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine].

### Claim 6 (depends on 1)

A method according to claim 1 wherein said therapeutically effective dose of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] is sufficient to provide a Cmax plasma level of between about 0.17 and about 44 nanomolar.

### Claim 7 (depends on 6)

A method according to claim 6 wherein said therapeutically effective dose is sufficient to provide a Cmax plasma level of between about 0.6 and about 15 nanomolar.

### Claim 8

A method of ameliorating cognitive deficits in subjects with schizophrenia comprising:
identifying a subject with schizophrenia;
administering to said subject at least one therapeutically effective dose of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine];
wherein said dose is in the range of about 0.0005 milligram to about 2.0 milligram.

### Claim 9 (depends on 8)

A method according to claim 8 additionally comprising
determining the duration of the amelioration of cognitive deficits;
administering additional therapeutically effective doses of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] at intervals sufficient to maintain said amelioration of cognitive deficits.

### Claim 10 (depends on 1)

A method according to claim 1 wherein said therapeutically effective dose is selected from about 0.0005 mg to about 0.026 mg; about 0.0261 mg to about 0.05 mg; about 0.051 mg to about 0.1 mg; about 0.11 mg to about 0.18 mg; about 0.181 mg to about 0.25 mg; about 0.251 mg to about 0.5; about 0.51 mg to about 0.7 mg; about 0.71 mg to about 0.85 mg; about 0.851 mg to about 1 mg; about 1.01 mg to about 1.15 mg; about 1.151 mg to about 1.35 mg; about 1.351 mg to about 1.45 mg; about 1.451 mg to about 1.6 mg; about 1.61 mg to about 1.75 mg; about 1.751 mg to about 1.87 mg, or about 1.871 mg to about 2 mg.

### Claim 11

A pharmaceutical composition comprising an amount of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] between about 0.0005 milligram and about 2.0 milligram per unit dose together with at least one pharmaceutically-acceptable excipient, diluent, or carrier.

### Claim 12 (depends on 11)

A pharmaceutical composition according to claim 11 comprising:
a therapeutically effective amount of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] sufficient to provide a Cmax plasma level of between about 0.17 and about 44 nanomolar per unit dose.

### Claim 13 (depends on 12)

A pharmaceutical composition according to claim 12 wherein said therapeutically effective amount of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] is sufficient to provide a Cmax plasma level of between about 0.6 and about 15 nanomolar.

### Claim at position 14

14-25. (canceled)

### Claim 26 (depends on 2)

A method according to claim 2 wherein said therapeutically effective dose is selected from about 0.0005 mg to about 0.026 mg; about 0.0261 mg to about 0.05 mg;
about 0.051 mg to about 0.1 mg; about 0.11 mg to about 0.18 mg; about 0.181 mg to about 0.25 mg; about 0.251 mg to about 0.5; about 0.51 mg to about 0.7 mg; about 0.71 mg to about 0.85 mg; about 0.851 mg to about 1 mg; about 1.01 mg to about 1.15 mg; about 1.151 mg to about 1.35 mg; about 1.351 mg to about 1.45 mg; about 1.451 mg to about 1.6 mg; about 1.61 mg to about 1.75 mg; about 1.751 mg to about 1.87 mg, or about 1.871 mg to about 2 mg.

### Claim 27 (depends on 3)

A method according to claim 3 wherein said therapeutically effective dose is selected from about 0.0005 mg to about 0.026 mg; about 0.0261 mg to about 0.05 mg; about 0.051 mg to about 0.1 mg; about 0.11 mg to about 0.18 mg; about 0.181 mg to about 0.25 mg; about 0.251 mg to about 0.5; about 0.51 mg to about 0.7 mg; about 0.71 mg to about 0.85 mg; about 0.851 mg to about 1 mg; about 1.01 mg to about 1.15 mg; about 1.151 mg to about 1.35 mg; about 1.351 mg to about 1.45 mg; about 1.451 mg to about 1.6 mg; about 1.61 mg to about 1.75 mg; about 1.751 mg to about 1.87 mg, or about 1.871 mg to about 2 mg.

### Claim 28 (depends on 4)

A method according to claim 4 wherein said therapeutically effective dose is selected from about 0.0005 mg to about 0.026 mg; about 0.0261 mg to about 0.05 mg; about 0.051 mg to about 0.1 mg; about 0.11 mg to about 0.18 mg; about 0.181 mg to about 0.25 mg; about 0.251 mg to about 0.5; about 0.51 mg to about 0.7 mg; about 0.71 mg to about 0.85 mg; about 0.851 mg to about 1 mg; about 1.01 mg to about 1.15 mg; about 1.151 mg to about 1.35 mg; about 1.351 mg to about 1.45 mg; about 1.451 mg to about 1.6 mg; about 1.61 mg to about 1.75 mg; about 1.751 mg to about 1.87 mg, or about 1.871 mg to about 2 mg.

### Claim 29 (depends on 5)

A method according to claim 5 wherein said therapeutically effective dose is selected from about 0.0005 mg to about 0.026 mg; about 0.0261 mg to about 0.05 mg; about 0.051 mg to about 0.1 mg; about 0.11 mg to about 0.18 mg; about 0.181 mg to about 0.25 mg; about 0.251 mg to about 0.5; about 0.51 mg to about 0.7 mg; about 0.71 mg to about 0.85 mg; about 0.851 mg to about 1 mg; about 1.01 mg to about 1.15 mg; about 1.151 mg to about 1.35 mg; about 1.351 mg to about 1.45 mg; about 1.451 mg to about 1.6 mg; about 1.61 mg to about 1.75 mg; about 1.751 mg to about 1.87 mg, or about 1.871 mg to about 2 mg.
